Paclitaxel
- TRADE NAMES: Abraxane; Paclimer; Paxene; Taxol (Bristol-Myers Squibb)
- INDICATIONS: Breast cancer and metastatic carcinoma of the ovary
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Taxane
- HALF-LIFE: 5–17 hours
Atazanavir, Bexarotene, Buspirone, Carbamazepine, Cisplatin, Clarithromycin, Delavirdine, Doxorubicin, Efavirenz, Eletriptan, Felodipine, Gadobenate, Gemfibrozil, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lovastatin, Nefazodone, Nelfinavir, Repaglinide, Rifampin, Ritonavir, Rosiglitazone, Saquinavir, Sildenafil, Simvastatin, Telithromycin, Teriflunomide, Thalidomide, Trastuzumab, Triazolam
PREGNANCY CATEGORY: D
Nab-paclitaxel is nanoparticle albumin–bound paclitaxel.
Studies have shown that elderly patients have an increased risk of severe myelosuppression, severe neuropathy and a higher incidence of cardiovascular events.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of albumin-bound paclitaxel in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/15/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric